Tonix Intangible Assets vs Long Term Debt Analysis
TNXP Stock | USD 0.16 0.01 5.88% |
Tonix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Tonix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tonix Pharmaceuticals is a good investment. Please check the relationship between Tonix Pharmaceuticals Intangible Assets and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
Intangible Assets vs Long Term Debt
Intangible Assets vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tonix Pharmaceuticals Intangible Assets account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Tonix Pharmaceuticals' Intangible Assets and Long Term Debt is 0.52. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Tonix Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Tonix Pharmaceuticals' Intangible Assets and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Tonix Pharmaceuticals Holding are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Intangible Assets i.e., Tonix Pharmaceuticals' Intangible Assets and Long Term Debt go up and down completely randomly.
Correlation Coefficient | 0.52 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Long Term Debt
Long-term debt is a debt that Tonix Pharmaceuticals has held for over one year. Long-term debt appears on Tonix Pharmaceuticals Holding balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Tonix Pharmaceuticals Holding balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from Tonix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tonix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. At this time, Tonix Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 06/01/2024, Enterprise Value Over EBITDA is likely to grow to 0.08, while Enterprise Value is likely to drop (8.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 92.3M | 112.1M | 117.1M | 123.0M | Cost Of Revenue | 92.3M | 112.1M | 9.0M | 8.6M |
Tonix Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Tonix Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tonix Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.6M | 98.2M | 240.9M | 225.7M | 154.5M | 162.2M | |
Other Current Liab | 1.0M | 2.5M | 5.1M | 6.4M | 9.5M | 10.0M | |
Total Current Liabilities | 5.1M | 9.8M | 21.7M | 18.2M | 18.9M | 19.8M | |
Total Stockholder Equity | 9.4M | 87.6M | 218.7M | 207.2M | 105.5M | 53.9M | |
Net Debt | (10.9M) | (75.8M) | (177.7M) | (119.5M) | (15.1M) | (15.9M) | |
Retained Earnings | (217.1M) | (267.5M) | (359.8M) | (470.0M) | (600.7M) | (570.6M) | |
Cash | 11.2M | 77.1M | 178.7M | 120.2M | 24.9M | 37.7M | |
Cash And Short Term Investments | 11.2M | 77.1M | 178.7M | 120.2M | 24.9M | 39.9M | |
Net Receivables | 1.0M | 7.6M | 7.7M | 8.0M | 4.6M | 3.7M | |
Common Stock Total Equity | 3K | 9K | 206K | 496K | 570.4K | 598.9K | |
Common Stock Shares Outstanding | 8.0K | 473.0K | 1.8M | 5.7M | 17.0M | 17.9M | |
Liabilities And Stockholders Equity | 14.6M | 98.2M | 240.9M | 225.7M | 154.5M | 162.2M | |
Other Stockholder Equity | 226.5M | 355.0M | 578.1M | 677.3M | 706.4M | 741.7M | |
Total Liab | 5.1M | 10.5M | 22.2M | 18.5M | 48.9M | 51.4M | |
Total Current Assets | 13.9M | 88.0M | 189.0M | 130.8M | 47.8M | 44.4M | |
Common Stock | 9K | 206K | 496K | 76K | 59.0K | 67.6K | |
Accounts Payable | 3.1M | 4.6M | 13.3M | 8.1M | 3.8M | 3.2M | |
Net Tangible Assets | 9.3M | 87.5M | 218.7M | 207.2M | 238.3M | 250.2M | |
Property Plant And Equipment Net | 390K | 9.8M | 51.5M | 94.5M | 94.9M | 99.6M | |
Current Deferred Revenue | 704K | 2.2M | 2.8M | 3.3M | 3.0M | 1.7M | |
Non Current Assets Total | 610K | 10.2M | 51.9M | 94.9M | 106.7M | 112.0M | |
Retained Earnings Total Equity | (188.5M) | (217.1M) | (267.5M) | (359.8M) | (323.8M) | (307.6M) | |
Non Current Liabilities Total | 6K | 716K | 467K | 328K | 30.0M | 31.6M | |
Capital Surpluse | 212.2M | 226.5M | 355.0M | 578.1M | 664.9M | 698.1M | |
Other Current Assets | 2.7M | 10.9M | 10.4M | 10.5M | 4.1M | 3.6M | |
Property Plant And Equipment Gross | 390K | 9.8M | 51.9M | 96.2M | 100.2M | 105.2M | |
Accumulated Other Comprehensive Income | (46K) | (62K) | (92K) | (167K) | (232K) | (220.4K) | |
Property Plant Equipment | 34K | 9.8M | 51.5M | 94.5M | 108.7M | 114.1M | |
Net Invested Capital | 9.4M | 87.6M | 218.7M | 207.2M | 112.1M | 107.4M | |
Net Working Capital | 8.8M | 78.2M | 167.3M | 112.6M | 28.9M | 27.4M | |
Capital Stock | 9K | 206K | 496K | 76K | 59K | 56.1K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Tonix Stock analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Tonix Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tonix Pharmaceuticals. If investors know Tonix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tonix Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.82) | Revenue Per Share 0.295 | Return On Assets (0.42) | Return On Equity (0.72) |
The market value of Tonix Pharmaceuticals is measured differently than its book value, which is the value of Tonix that is recorded on the company's balance sheet. Investors also form their own opinion of Tonix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tonix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tonix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tonix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tonix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tonix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tonix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.